Vacuum foam drying for preservation of lasota virus: Screening of foaming agent and cycle optimization

Indian Journal of Biotechnology

Volumn 5, Issue 4, 2006, Pages 491-497

  Pisal, S S ^a   Wawde, G M ^a   Bandivadekar, M M ^a   Hajare, A A ^b   More, H N ^b   Kadam, S S ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

^b BHARATI VIDYAPEETH COLLEGE OF PHARMACY   (India)

Author keywords

Cycle optimization; Foamability; Lasota; Pluronic; Vacuum foam drying

Indexed keywords

FOAMING AGENT; LASOTA VACCINE; POLOXAMER; UNCLASSIFIED DRUG; VIRUS VACCINE;

ALPHA HELIX; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; INFRARED RADIATION; LASOTA; NONHUMAN; PARAMYXOVIRUS; VACUUM;

EID: 33845252509     PISSN: 09725849     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Skrabanja A T P & De Meere A L J, Lyophilization of biotechnology products, PDA J Pharm Sci Technol, 48 (1994) 311-317.
2. Mumenthaler M & Hsu C C, Feasibility study on spray dried protein pharmaceuticals: Recombinant human growth hormone and tissue type plasminogen activator, Pharm Res, 11 (1994) 12-20.
3. Strambini G B & Gabellerri E, Proteins in frozen solutions: Evidence of ice induced partial unfolding, Biophys J, 70(1996) 971-976.
4. Amal A T& Robert W, Integrity of crystalline lysozyme exeeds that of spray dried form, Int J Pharm, 247( 2002) 79-90.
5. Arakawa T & Prestrelskis J, Factors affecting short term and long term stabilities of proteins, Adv Drug Del Rev, 10(1993) 1-28.
6. Wang W, Lyophilization and development of solid protein pharmaceuticals, Int J Pharm, 203 (2000) 1-60.
7. Separovic F & Lam Y H, A solid state NMR study of protein hydration and stability, Pharm Res, 15(1998) 1816-1821.
8. Rey L & May J C, Freeze-Drying and lyophilization of pharmaceutical and biological products (Marcel Decker Inc., New York), 1999, 267-335.
9. Wu S & Leung D, Degradation mechanism of lyophilized basic fibroblast growth factor (BFGF) protein in sugar formulation, Pharm Sci, 1 Suppl (1998) S-539.
10. Katakam M & Robillard P, Effects of moisture and lyophilization cycle on aggregation of a monoclonal antibody product, Pharm Sci, 1 Suppl (1998) S-543.
11. Bronshtein V, Industrial scale barrier technology for preservation of sensitive biological materials at ambient temperatures, US Patent No. 6,509,146, (to Universal Preservation Technologies, Inc., San Diego, CA) February 17, 2004.
12. Pisal S S & Mane J J, Effect of excipients on product characteristics and structure of lyophilized lasota vaccine, Indian J Biotechnol, 4 (2005) 106-114.
13. Moreng R E & Avens J S, Poultry science and production (Reston Publishing Company, Inc., Virginia) 1985, 143-152.
14. Allan W H & Lancaster J E, Newcastle disease vaccines (FAO, UN, Rome) 1978, 52-54.
15. th Natl Conf on Surfactants, Emulsions and Biocolloids, held on September 2003, Mumbai, India.
16. Alexander D J, Newcastle disease (Kluwer Academic Publisher, London) 1988.
17. rd Indian Pharm Congr, held on December 2001, New Delhi, India.
18. Allan W H & Lancaster J E, Newcastle disease vaccines (FAO, UN, Rome), 1978, 33-41.
19. Bedu-Addo F K, Understanding lyophilization formulation development, Pharm Technol (Lyophilization), (2004) 10-18.
20. Wang W, Instability, stabilization, and formulation of liquid protein pharmaceuticals, Int J Pharm, 185 (1999) 129-188.
21. Townsend M W & DeLuca P P, Stability of ribonuclease A in solution and the freeze-dried state, J Pharm Sci, 79(1990) 1083-1086.
22. Vrkljan M & Foster T M, Thermal stability of low molecular weight urokinase during heat treatment: Effect of polymeric additives, Pharm Res, 11 (1994) 1004-1008.
23. Costantio H R & Langer R, Moisture-induced aggregation of lyophilized insulin, Pharm Res, 11(1995) 21-29.
24. Petra E & Julia Y, Porous carriers for biomedical applications based on alginate hydrogels, Biomaterials, 21 (2000) 1921-1927.
25. Pandit N K & Kisaka J, Loss of gelation ability of pluronic F127 in the presence of some salts, Int J Pharm, 145 (1996)129-136.
26. Kibbe H A. Handbook of pharmaceutical excipients (Am Pharm Assoc, Pharmaceutical Press; London) 2000.
27. Yong H L & Marc B B, Investigation of the stabilization of freeze-dried lysozyme and the physical properties of the formulations, Euro J Pharm Biopharm, 58 (2004) 15-24.
28. Jun C & Haesun P, Synthesis of superporous hydrogels: Hydrogels with fast swelling and superabsorbent properties, J Biomed Mat Res, 44 (1999) 53-62.
29. House J A & Mariner J C, Stabilization of rinderpest vaccine by modification of the lyophilization process, Dev Biol Stand, 74 (1996) 235-244.
30. Levine H & Slade L, Another view of trehalose for drying and stabilizing biological materials, Biopharm, 5 (1992)36-40.
31. Pisal S S & Reddy P, Nasal melatonin gels using pluronic PF127 for chronobiological treatment of sleep disorders, Indian J Biotechnol, 3 (2004) 369-377.
32. Vadnere M & Amidon G, Thermodynamic studies on the gel-sol transition of some pluronic polyols, Int J Pharm, 22 (1984) 207-218.